Cargando…
N6-Methyladenosine RNA modification in cerebrospinal fluid as a novel potential diagnostic biomarker for progressive multiple sclerosis
BACKGROUND: Progressive multiple sclerosis (PMS) is an uncommon and severe subtype of MS that worsens gradually and leads to irreversible disabilities in young adults. Currently, there are no applicable or reliable biomarkers to distinguish PMS from relapsing–remitting multiple sclerosis (RRMS). Pre...
Autores principales: | Ye, Fei, Wang, Tianzhu, Wu, Xiaoxin, Liang, Jie, Li, Jiaoxing, Sheng, Wenli |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8296732/ https://www.ncbi.nlm.nih.gov/pubmed/34294105 http://dx.doi.org/10.1186/s12967-021-02981-5 |
Ejemplares similares
-
MicroRNAs in blood and cerebrospinal fluid as diagnostic biomarkers of multiple sclerosis and to monitor disease progression
por: Martinez, Bridget, et al.
Publicado: (2019) -
Multiple Sclerosis Cerebrospinal Fluid Biomarkers
por: Giovannoni, Gavin
Publicado: (2006) -
Diagnostic Cerebrospinal Fluid Biomarker in Early and Late Onset Multiple Sclerosis
por: Konen, Franz Felix, et al.
Publicado: (2022) -
Development and Validation of a Five-Gene Signature to Predict Relapse-Free Survival in Multiple Sclerosis
por: Ye, Fei, et al.
Publicado: (2020) -
Cerebrospinal fluid biomarkers of disease activity and progression in amyotrophic lateral sclerosis
por: Dreger, Marie, et al.
Publicado: (2022)